The purpose of this clinical trial is to evaluate the effect of hydroxytyrosol 10 mg/day administered for 4 weeks in pregnant individuals with hypertension. This study will assess whether hydroxytyrosol increases serum superoxide dismutase levels, reduces uterine artery Doppler pulsatility and resistance indices, and improves brachial artery flow-mediated dilation. Participants will be randomly assigned to receive either hydroxytyrosol or a matching placebo. Both products will be visually identical to ensure blinding. Participants will take two capsules daily for 4 weeks and attend two study visits for assessments and follow-up.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in superoxide dismutase (SOD) levels measured by colorimetric assay from baseline to week 4.
Timeframe: Baseline and Week 4
Change in Pulsatility Index (PI) of the uterine artery Doppler from baseline to week 4.
Timeframe: Baseline and Week 4
Change in Resistance Index (RI) of the uterine artery Doppler from baseline to week 4.
Timeframe: Baseline and Week 4
Change in flow-mediated dilation (FMD) of brachial artery measured by an ultrasound from baseline to week 4.
Timeframe: Baseline and Week 4